Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Jensen

Internal Medicine Dalton, GA Medical Doctor

NPI 1235136052 CMS profile 236789

914 Vista Drive, Dalton, GA 30721

Open in the dashboard

General payments

$12,264

732 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Jensen of Dalton, GA is reported in the CMS Open Payments database as having received $12,264 across 732 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,457 79
2024 General $1,780 89
2023 General $1,715 105
2022 General $1,882 126
2021 General $1,925 119
2020 General $1,648 98
2019 General $1,856 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Jensen
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eric Jensen were reported at $1,457. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eric Jensen Internal Medicine median Middle half National median
2019 $1,856 $159 $48–$570 $163
2020 $1,648 $119 $33–$402 $114
2021 $1,925 $135 $37–$521 $132
2022 $1,882 $141 $42–$496 $149
2023 $1,715 $149 $45–$519 $160
2024 $1,780 $154 $47–$537 $164
2025 $1,457 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,766 112 payments
  2. Pfizer Inc. $1,330 85 payments
  3. AbbVie, Inc. $1,168 78 payments
  4. AstraZeneca Pharmaceuticals LP $942 40 payments
  5. Novo Nordisk Inc $786 52 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $733 43 payments
  7. Abbott Laboratories $647 31 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $486 23 payments
  9. GlaxoSmithKline, LLC. $363 23 payments
  10. Sanofi-Aventis U.S. LLC $339 24 payments
  11. Other $3,704 221 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,180 727 payments
  2. Gift $59 1 payment
  3. Education $25 4 payments
Products named General payments · program years 2019–2025
  1. Repatha $829 55 payments
  2. EVENITY $709 51 payments
  3. Ozempic $655 44 payments
  4. RYBELSUS $631 42 payments
  5. FARXIGA $555 24 payments
  6. Prolia $534 54 payments
  7. AIMOVIG $514 27 payments
  8. FreeStyle Libre 3 $506 22 payments
  9. Kerendia $486 23 payments
  10. NURTEC ODT $486 31 payments
  11. Other $10,840 680 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 201 drugs

Part D claims

16,567

Median for Emergency Medicine: 88

Drug cost

$1,716,847

Median for Emergency Medicine: $590

Branded share of claims

22.9%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 277 $259,540
Ozempic Semaglutide Brand 163 $162,827
Trulicity Dulaglutide Brand 103 $158,896
Jardiance Empagliflozin Brand 170 $148,826
Mounjaro Tirzepatide Brand 123 $148,560
Farxiga Dapagliflozin Propanediol Brand 100 $101,273
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 65 $57,428
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 81 $55,440
Otezla Apremilast Brand 12 $54,770
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 50 $47,633

The 10 drugs with the highest cost, of 201 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$419,308

Of which drugs: $97,002

Medicare patients

651

Average age 77

Services billed

15,496

296 women, 355 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 34%
Ischemic heart disease 32%
Chronic kidney disease 27%
Atrial fibrillation 20%
Heart failure 18%
Cancer 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 135 135 $38,872
Injection, denosumab, 1 mg J0897 Office 18 1,800 $36,115
Vaccine for influenza for injection into muscle 90662 Office 256 259 $20,981
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 131 699 $444
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 129 688 $52
Injection, ketorolac tromethamine, per 15 mg J1885 Office 22 58 $28
Injection, ceftriaxone sodium, per 250 mg J0696 Office 35 67 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $153
$153 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $139
$139 170 —
VRAYLAR
  • AbbVie, Inc. $102
$102 — —
RYBELSUS
  • Novo Nordisk Inc $86
$86 19 —
Ozempic
  • Novo Nordisk Inc $86
$86 163 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

732 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record